Pericardial Synovial Sarcoma: Case Report, Literature Review and Pooled Analysis

• Published in: In vivo (Athens) Vol. 33; no. 5; pp. 1531 - 1538
• Main Authors: Duran-Moreno, Jose, Kampoli, Katerina, Kapetanakis, Emmanouil I, Mademli, Maria, Koufopoulos, Nektarios, Foukas, Periklis G, Kostopanagiotou, Kostas, Tomos, Periklis, Koumarianou, Anna
• Format: Journal Article
• Language: English
• Published: Greece International Institute of Anticancer Research 01.09.2019
• Subjects: Biopsy; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Middle Aged; Pericardial Effusion - pathology; Pericardium - pathology; Positron-Emission Tomography; Radiosurgery; Sarcoma, Synovial - diagnosis; Sarcoma, Synovial - mortality; Sarcoma, Synovial - therapy; Pericardial synovial sarcoma; pazopanib; chemotherapy; stereotactic radiosurgery
• ISSN: 0258-851X; 1791-7549; 1791-7549
• DOI: 10.21873/invivo.11633

Pericardial synovial sarcomas (PSS) are very rare tumors, with dismal prognosis and limited data. We describe the clinical features and identify prognostic factors of primary PSS. We describe the case of a 56-year-old male patient with PSS managed by the multidisciplinary team of thoracic oncology. The therapeutic plan comprised surgery, chemotherapy, stereotactic radiosurgery and targeted therapy, with excellent results. Data from 37 cases reported in English during the past 20 years were gathered and analyzed. PSS was found to occur at a mean age of 36±17.082 (range=13-67) years. Survival analysis was performed on 20 cases with follow-up of at least 6 months. Only complete resection of the tumor seems to be an independent prognostic factor. To our knowledge, this is the first report on the safety and effectivity of pazopanib in PSS and may provide guidance for similar cases in the future.